SciSparc

SPRC

Market cap $5.67M

TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding term sheet (the “Term Sheet”) with an Israeli-based pioneering quantum computing bio data company focused on quantum-enabled clinical analytics (the “Target Company"). Pursuant to the Term Sheet, NeuroThera will acquire a 55% equity interest in the Target Company from certain selling shareholders of the Target Company (the “Selling Shareholders”), calculated on a post transaction fully diluted basis, in consideration for the issuance to the Selling Shareholders of that amount of common shares, no par value per share, of NeuroThera equal to 40% of NeuroThera's share capital, calculated on a non-diluted  basis (the “Acquisition”).

December 2, 2025 – TheNewswire - Vancouver, British Columbia, Canada -  Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera” or the “ Company”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that it has entered into a non-binding term sheet (the “Term Sheet”) with a pioneering quantum computing bio data company focused on quantum-enabled clinical analytics (the “Target Company"). Under the terms of the Term Sheet, Neurothera will acquire a 55% equity interest in the Target Company, calculated on a post transaction fully diluted basis, from certain selling shareholders of the Target Company (the “Selling Shareholders”), in consideration for the issuance to the Selling Shareholders of that amount of common shares in the capital of Neurothera (“Common Shares”) as is equal to 40% of the Common Shares, calculated on a non-diluted post transaction basis (the “Acquisition”). By harnessing the principles of quantum computing, bio data can be stored, manipulated, and analyzed far more efficiently than existing technologies, potentially revolutionizing the field through accelerated processing and enhanced insights. This innovative approach is based on key quantum phenomena such as superposition, entanglement, and inherent parallelism to deliver faster computations and superior machine learning performance. In turn, it strives to redefine clinical trials via quantum intelligence, seamlessly integrating quantum computing with bioinformatics and clinical data science to potentially unlock precision and speed in medical research and development.

TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., recently announced the signing of a binding term sheet to acquire treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo”).

TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., today announced the signing of a binding term sheet to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo”).

TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. by filing an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), targeting depression.

November 19, 2025 – TheNewswire - Vancouver, British Columbia, Canada -  Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera” or the “ Company”), a clinical-stage biotech company and an wholly-own subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) has filed an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression. The patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine Inc. This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization , major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.

TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the closing of the transactions under the asset and share purchase agreement by and among the Company, Miza III Ventures Inc. and SciSparc Nutraceuticals Inc. (the “Agreement”). Pursuant to the Agreement, SciSparc received a controlling interest in Neurothera Labs Inc. (formerly known as Miza III Ventures Inc.) (TSXV:NTLX) (“Neurothera”), a publicly traded company on the TSX Venture Exchange (the “TSXV”) in Canada, and the Company transferred to Neurothera its advanced clinical stage pharmaceutical portfolio and its equity stake of approximately 51% in SciSparc Nutraceuticals Inc. (collectively, the “Target Assets”).

TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the sale to N2OFF, Inc. (Nasdaq: NITO) (“N2OFF”) of SciSparc's majority owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”).

TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, recently announced that on September 16, 2025 the board of directors resolved to initiate the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology (the “Initiative”). This new program aims to transform drug discovery by potentially achieving unprecedented accuracy in predicting protein structures and interactions with their ligands, potentially paving the way for breakthroughs in structural biology and personalized medicine.

This press release is issued pursuant to National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues . Vancouver, British Columbia – October 22, 2025 – TheNewswire - Pursuant to the requirements of applicable securities laws, SciSparc Ltd. (“ SciSparc ”) , a corporation incorporated under the laws of the State of Israel and listed on the NASDAQ under the trading symbol “SPRC” with an office address of 20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, 6971916, Israel, reports that on October 22, 2025, SciSparc acquired 63,300,000 common shares in the capital of NeuroThera Labs Inc. (formerly Miza III Ventures Inc.) (the “ Company ”) (“ Shares ”), 4,000,000 common share purchase warrants (“ Payment Warrants ”), and 48,000,000 contingent rights of the Company (“ Contingent Rights ”) pursuant to the completion of a reverse takeover involving the transfer to the Company all of the shares of SciSparc Nutraceuticals Inc. (“ SNI ”) held by SciSparc (representing 50.86% of the issued and outstanding shares of SNI) and certain assets of SciSparc (the “ Qualifying Transaction ”).